Liver Transplantation Center

Hospitalization: Yes Length of Stays: 0 ~ 0days

Appointment: Yes

Price: Price must be evaluated by physicians. Foreign Exchange Rate(The information is indicative only)

Payments: Cach, Credit Card

Treatment introduction
Various liver disease treatments: Children: biliary atresia, neonatal hepatitis, choledochal cyst, congenital metabolic disorders, polycystic liver disease, liver abscess, liver cancer, acute liver failure, and Budd-Chiari syndrome. Adult: viral hepatitis and cirrhosis, liver cancer, acute liver failure, alcoholic cirrhosis, intrahepatic stones, Budd-Chiari syndrome, portal hypertension, liver abscess. Living donor liver transplantation (LDLT) involves taking part of the liver of a healthy relative and transplanting it to patients with end-stage liver disease. Unlike the kidneys, the liver is only a single organ and it entails complex surgical techniques with meticulous dissection of the small blood vessels and bile ducts to maximize function. After continuous clinical trials and animal experiments, the first living donor liver transplant in Taiwan was performed on June 17, 1994. Thereafter, LDLT brought new hope for patients with liver disease. Due to limited organ donation in Taiwan, many patients pass away while waiting for an organ transplant. With LDLT, the patients can obtain a liver anytime from a willing and suitable relative. Living donor liver transplantation has the following benefits: (1) It can be carried out under the most suitable timing and conditions between the donor and recipient. (2) The liver graft has a high level of freshness and better function. (3) Lower incidence of transplant rejection. (4) The liver volume, vascular and bile duct anatomy, etc. can be accurately calculated and matched before surgery. Kaohsiung Chang Gung Memorial Hospital has developed a number of innovative techniques and strategies for living donor liver transplantation and has achieved excellent results. These include saphenous vein graft angioplasty, hepatic vein angioplasty, prevention of hepatitis B virus transmission, innovative technology in treating portal vein thrombosis, and microsurgical vascular and biliary reconstruction. As the highest in the world, the five-year survival rate of 100 pediatric patients receiving living donor liver transplantation was 98% for biliary atresia (Am J Transplant, 2006); For patients with liver cancer that surpasses Milan Criteria for liver transplantation, they receive local treatment first followed by living donor liver transplantation to achieve a five-year survival rate of 90% (Transplantation, 2008).
As of October 2018, a total of 1,800 liver transplants were performed including 1,570 living donor liver transplants, with patient survival rate surpassing that of Europe, America, and Japan as the highest in the world. Additionally, the five-year survival rate is 98% for biliary atresia, 91% for hepatitis B virus- related cirrhosis, and 90% for liver cancer.